Development and Clinical Evaluation of a Rapid Point of Care Test for Ebola Virus Infection in Humans
Authors:
- Zheng WangZWZheng Wang
- Richard S. BennettRBRichard S. Bennett
- Michele RoehlerMRMichele Roehler
- Geraldine GuillonGGGeraldine Guillon
- Mark J. FischlMFMark J. Fischl
- Mary C. DonadiMDMary C. Donadi
- Jim MakovetzJMJim Makovetz
- Natalie HolmesNHNatalie Holmes
- Toral ZaveriTZToral Zaveri
- Eamon ToolanETEamon Toolan
- Heather L. GontzHGHeather L. Gontz
- Graham D. YearwoodGYGraham D. Yearwood
Open Access
Abstract
The genus Ebolavirus contains multiple species of viruses that are highly contagious and lethal, often causing severe hemorrhagic fever. To minimize the global threat from Ebola virus disease (EVD), sustainable, field-appropriate tools are needed to quickly screen and triage symptomatic patients and conduct rapid screening of cadavers to ensure proper handling of human remains. The OraQuick® Ebola Rapid Antigen Test is an in vitro diagnostic single-use immunoassay for the qualitative detection of Ebola virus antigens that detects all known species within the genus Ebolavirus. Here, we report the performance of the OraQuick® Ebola Rapid Antigen Test and provide a comparison of its performance with other rapid diagnostic tests (RDTs) for EVD. OraQuick® Ebola demonstrated clinical sensitivity of 84.0% in archived EVD patient venous whole-blood (WB) samples, 90.9% in Ebola virus-infected monkey fingerstick samples, and 97.1% in EVD patient cadaver buccal swabs, as well as clinical specificity of 98.0–100% in venous WB samples and 99.1–100% in contrived saliva samples. It is the only 510(k)-cleared Ebola rapid test, has analytical sensitivity as good as or better than all RDT comparators for EVD, and can detect the Sudan virus. Our data demonstrate that the OraQuick® Ebola Rapid Antigen Test is a sensitive and specific assay that can be used for rapid detection of EBOV in humans and could support efforts for EVD-specific interventions and control over outbreaks.Keywords
Funding Information
- Biomedical Advanced Research and Development Authority (HHSO100201500009C, NOR15003-001-0000, HHSN272200700016I)
- National Institute of Allergy and Infectious Diseases (HHSO100201500009C, NOR15003-001-0000, HHSN272200700016I)
- National Institute of Allergy and Infectious Diseases (HHSO100201500009C, NOR15003-001-0000, HHSN272200700016I)
This publication has 12 references indexed in Scilit:
- Institutional trust and misinformation in the response to the 2018–19 Ebola outbreak in North Kivu, DR Congo: a population-based surveyThe Lancet Infectious Diseases, 2019
- Comparative performance of four rapid Ebola antigen-detection lateral flow immunoassays during the 2014-2016 Ebola epidemic in West AfricaPLOS ONE, 2019
- Diagnostics for filovirus detection: impact of recent outbreaks on the diagnostic landscapeBMJ Global Health, 2019
- Speedy Ebola tests help contain Africa’s latest outbreakNature, 2018
- EBOLA Ag K-SeT rapid test: field evaluation in Sierra LeoneClinical Microbiology and Infection, 2018
- High dose sertraline monotherapy fails to protect rhesus macaques from lethal challenge with Ebola virus MakonaScientific Reports, 2017
- Animal Models of Ebolavirus Infection.2017
- Strategies in Ebola virus disease (EVD) diagnostics at the point of careCritical Reviews in Microbiology, 2017
- Diagnosis of Ebola Virus Disease: Past, Present, and FutureClinical Microbiology Reviews, 2016
- Development of an Immunochromatography Assay (QuickNavi-Ebola) to Detect Multiple Species of EbolavirusesThe Journal of Infectious Diseases, 2016